<?xml version="1.0" encoding="UTF-8"?>
<ref id="B28-vaccines-07-00072">
 <label>28.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Pérez</surname>
    <given-names>O.</given-names>
   </name>
   <name>
    <surname>Romeu</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Cabrera</surname>
    <given-names>O.</given-names>
   </name>
   <name>
    <surname>González</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Batista-Duharte</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Labrada</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Pérez</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Reyes</surname>
    <given-names>L.M.</given-names>
   </name>
   <name>
    <surname>Ramírez</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Sifontes</surname>
    <given-names>S.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Adjuvants are key factors for the development of future vaccines:lessons from the Finlay adjuvant platform</article-title>
  <source>Front. Immunol.</source>
  <year>2013</year>
  <volume>4</volume>
  <fpage>407</fpage>
  <pub-id pub-id-type="doi">10.3389/fimmu.2013.00407</pub-id>
  <pub-id pub-id-type="pmid">24348475</pub-id>
 </element-citation>
</ref>
